Gaush Meditech Ltd

高视医疗科技有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2407)

VOLUNTARY ANNOUNCEMENT OCULAR FUNDUS CAMERAS OBTAINED MEDICAL DEVICE REGISTRATION CERTIFICATE IN CHINA

This announcement is made by Gaush Meditech Ltd (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis, to inform the shareholders and potential investors of the Company regarding the latest business development of the Group.

The board (the "**Board**") of directors (the "**Director(s)**") of the Company is pleased to announce that Gaush Neotech Ltd* (高視創新科技有限公司) ("**Gaush Neotech**"), a subsidiary of the Company, has recently obtained the medical device registration certificate for its "ocular fundus cameras" from the Jiangsu Medical Products Administration.

In the backdrop of growing aging population and the rising incidence of chronic diseases such as diabetes and hypertension, the number of patients with fundus diseases is increasing steadily. Fundus diseases such as diabetic retinopathy, age-related macular degeneration and glaucoma, may lead to irreversible visual impairment or even blindness if they are not intervened in time. However, traditional fundus examinations usually rely on mydriasis, which not only intensifies patient discomfort but also prolongs the examination time.

The ocular fundus cameras (Registration Certificate No.: Su Xie Zhu Zhun 20252161082) of Gaush Neotech approved this time integrates an intelligent imaging system and an innovative mydriasis-free HD imaging technology, which enables a full-process automated operation from focusing, photographing to image optimization. The device is equipped with intelligent tracking technology that automatically recognizes the position of pupils and focuses accurately. Its advanced optical system design allows contactless HD imaging, eliminating the discomfort caused by traditional mydriasis medication and rendering diagnostic-grade images that clearly show the microstructure of the retina with a single click. Its unique intelligent guidance system can automatically adjust the shooting parameters to adapt to different patient characteristics, with advanced image processing algorithms to automatically optimize the visual effects, and a fully closed inspection process to minimize human interference. The product strictly follows the international optical safety standards, optimizes the optical source and ergonomic design to ensure a safe and comfortable examination. Besides, it supports multiple image formats for storage and convenient data export, as well as perfect connection with information systems of hospitals.

This product is applicable for screening and diagnosis and long-term follow-up of diabetic retinopathy and other fundus diseases, which enables non-professional operators to easily perform professional fundus examination, truly realizing the intelligent diagnostic and treatment experience of "one-click shooting, automatic optimization", significantly enhancing the ophthalmic diagnostic and treatment capacity of primary medical institutions, and promoting the popularization of eye health screening.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Gaush Meditech Ltd
Mr. Gao Tieta
Chairman and Executive Director

Hong Kong, June 19, 2025

As of the date of this announcement, the Board comprises Mr. Gao Tieta as Chairman and executive Director, Mr. Liu Xinwei, Mr. Zhao Xinli, Mr. Zhang Jianjun and Ms. Li Wenqi as executive Directors, Dr. David Guowei Wang as non-executive Director, and Mr. Feng Xin, Mr. Wang Li-Shin and Mr. Chan Fan Shing as independent non-executive Directors.

* *For identification purpose only*